Comparative Pharmacology
Head-to-head clinical analysis: NORPACE CR versus QUINATIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORPACE CR versus QUINATIME.
NORPACE CR vs QUINATIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; decreases myocardial excitability and conduction velocity, and prolongs refractory period by blocking sodium channels.
Quinine acts by interfering with the parasite's ability to break down hemoglobin, leading to accumulation of toxic heme and parasite death. It also inhibits nucleic acid and protein synthesis in the parasite.
Disopyramide controlled-release: 200 mg orally every 12 hours; maximum 400 mg/day.
600 mg (base) orally every 8 hours for 7 days; or 10 mg/kg (base) intravenously loading dose over 1 hour, then 0.02 mg/kg/min continuous infusion for 3 days, then switch to oral.
None Documented
None Documented
Terminal elimination half-life: 6-12 hours (normal renal function); prolonged to 12-20 hours in renal impairment. In coronary artery disease, half-life may be extended due to reduced clearance.
Terminal elimination half-life 10-12 hours in healthy adults; prolonged in hepatic impairment.
Renal (50-57% unchanged), hepatic metabolism (30-40%), fecal (<10%). Dose adjustment required for CrCl <40 mL/min.
Renal: ~20% unchanged; hepatic metabolism (CYP3A4) major route; biliary/fecal: ~80% as metabolites.
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)